Life After Kidney Transplant: Immunosuppression, Diet and Long-Term Care

These patients do fairly well. CD4 count is checked and optimised before travel, with good medical management started well ahead of transplant so patients only travel once they fall into a suitable category. The immediate transplant risk in HIV-positive patients is similar to other patients, though later opportunistic-infection-related complications run somewhat higher, so immunosuppression is adjusted accordingly, for example avoiding routine ATG in favour of a gentler induction agent so immunity is not suppressed as heavily.

Yes, blood group-incompatible transplants are done routinely, though they remain the second choice after a compatible donor. The recipient's antibody titre against the donor's blood group determines eligibility: titres up to 1:8 are essentially as good as a compatible transplant, and even up to 1:64 respond to one or two sessions of plasmapheresis. Higher titres, above 1:128, need immunoadsorption column filtration to bring the level down before proceeding. The success rate is good but runs slightly below a fully compatible transplant, with roughly one in 50 patients experiencing hyperacute rejection.

Yes, HLA incompatibility alone is not a major problem, even between spouses with no HLA match at all. What actually determines eligibility is the cross match: a negative CDC and flow cross match clears the way for transplant. If CDC is negative but flow is positive, donor-specific antibody testing by the single antigen bead method quantifies the real risk, an MFI reading up to roughly 1,500-2,000 is not a concern, while higher readings call for plasmapheresis first. The key requirement is simply that there should be no antibodies against that particular HLA antigen.

Whenever a brain-dead donor is identified anywhere in Delhi NCR, India's national organ transplant authority (NOTTO) is notified and coordinates two brain stem death declarations roughly two hours apart, made jointly by the primary caregiver and a neurointensivist or equivalent specialist. Once the family consents, NOTTO allocates the organ from its waiting list strictly by turn order across hospitals, no single centre can claim it outside that process. From the first declaration to organ harvest is roughly a 12-hour process, with the recipient's dialysis and cross-match run in parallel so the transplant can proceed within six to twelve hours of harvest.

This is antibody-mediated rejection (AMR), one of two categories of acute rejection alongside cell-mediated rejection (ACR), and a kidney biopsy is needed to tell them apart. Treatment usually starts with methylprednisolone pulses, escalating to anti-thymocyte globulin or plasmapheresis if that isn't enough. In over a decade, hyperacute rejection has not been seen in blood-compatible transplants at this centre, and most rejection today is reversible when caught and treated promptly, the real danger comes from delayed treatment, not from the rejection episode itself.

Yes, without exception. Immunosuppression keeps the recipient's immune system from attacking the new kidney, and even a brief lapse, such as missing doses for a few days, can trigger a rejection episode.

Around 97% at one year, 93-95% at two years, 75-80% at ten years, and around 60% at fifteen years, based on outcomes at Dr. Rana's centre. Consistent long-term follow-up, including routine creatinine and urine testing every three months, is what protects these outcomes.